Treat Cancer at Any Stage

A Bold, Novel Drug Approach to Kill Tumors and Activate Immune Response

Treat locally, act globally. Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.

A Bold, Novel Drug Approach to Kill Tumors and Activate Immune Response to Treat Cancer at Any Stage

Treat locally, act globally. Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.

Tumor
Injection

DfuseRx℠ is our novel proprietary penetration enhancer platform technology that enables therapeutic agents to be injected directly into solid tumors for improved absorption.

Diffusion
Through Tumor

Once injected, DfuseRx enables the injected drug solution to disperse throughout the tumor and increases the drug’s diffusion into cancer cells.

Localized
Cell Death

The absorbed active agents in the injected tumor induce cancer cell death, without disruption of the cell membrane, in a manner that results in an influx of immune cells throughout the tumor.

System-wide
Immune Response

Tumor cell death exposes the immune system to antigens of the patient’s own cancer, inducing a personalized CD4+ and CD8+ T cell response, attacking the site of the former tumor while attacking distal cancer sites.

Increased
Survival

Exploratory analysis of data from a Phase 1/2 trial of relapsed and refractory solid tumor patients with a variety of cancers indicates an association between percent of tumor burden treated and survival.

Technology and Clinical Data

DfuseRxSM is our novel proprietary product discovery technology that enables drug compounds including cytotoxic agents to be injected directly into solid tumors with high absorption. The technology makes use of novel dispersion and cell penetration enhancer molecules that we have identified.
Play Video

Register for News Updates:

Subscribe to our company news email list and receive news as it is released. Your privacy is important, and your email address will be used only for this news distribution list.

Latest Tweets:

All #ASCO posters and presentations can be seen on the publications page on our website. http://www.intensitytherapeutics.com

At #ASCO22 three @IntensityInc abstacts were selected for 3 poster and 2 podium discussion session. Data in #sarcoma and #breastcancer for INT230-6 alone, and in other #Cancers combined with Keytruda and INT230-6 with Yervoy were shown.

At the same time INT230-6 data alone and combined with Keytruda was just discussed and presented at #ASCO22 in live podium discussion session. Dr. Jacob Thomas from USC was on the podium to answer questions.

Our drug INT23-6 data was just discussed and presented at #ASCO22 in live podium discussion session. Dr. Matthew Ingham from Columbia Presbyterian was on the podium to answer questions from the audience.

Please read today's news release at https://bit.ly/3tdZ4wl about our excellent data in #sarcoma reporting increased survival and favorable safety for our drug INT230-6

Load More...